Development of mechanistically distinct androgen receptor antagonists and degraders for the treatment of advanced castration resistant prostate cancerResearchAssociate Research Professor · Awarded by Department of Defense · 2015 - 2019
Evaluation of the therapeutic potential of combining VT464 and G1T38 in treatment-resistant prostate and breast cancer modelsResearchAssociate Research Professor · Awarded by Innocrin Pharmaceutical, Inc. · 2016 - 2017
- BMS Corporation
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.